

Shingles Vaccine Market Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax, SkyZoster), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine), By Region, And Segment Forecasts, 2021 - 2028

<https://marketpublishers.com/r/S29C80BA15CAEN.html>

Date: October 2021

Pages: 100

Price: US\$ 5,950.00 (Single User License)

ID: S29C80BA15CAEN

Abstracts

This report can be delivered to the clients within 72 Business Hours

Shingles Vaccine Market Growth & Trends

The global shingles vaccine market size is expected to reach USD 6.35 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.9% from 2021 to 2028. Increasing incidence of shingles and high awareness regarding shingles in developed countries are contributing to the market growth. According to the CDC, nearly one million cases of shingles are reported each year in the United States. Furthermore, one out of three individuals in the country will develop the disease in their lifetime.

The increasing adoption of vaccines and an increase in the recommendation of vaccination by different government regulatory bodies are expected to drive the market over the forecast period. For instance, in February 2019, the U.K. Joint Committee of Vaccination and Immunization (JCVI) has recommended the use of the recombinant vaccine to prevent shingles in adults aged 60 to 70 years old.

The inclusion of shingles vaccines in national immunization programs of several countries is anticipated to propel the demand for vaccines. For instance, the shingles vaccine is a part of the national immunization program in the U.K. since 2013. The U.K. is the first country in the European region to introduce shingles vaccine in the national

immunization program and it costs around USD 130 to the National Health Service (NHS) for each dose of the vaccine. Similarly, other countries such as the U.S., Italy, Australia, and some provinces of Canada and South Korea have also included the vaccine in their immunization program.

Besides, favorable initiatives undertaken by market players and regulatory bodies to increase the awareness among people who are at risk of developing the disease are expected to fuel the market growth over the coming years. For instance, GlaxoSmithKline plc. has launched a campaign to increase vaccination rates among older adults by educating people about the benefits associated with vaccination.

The high efficacy of vaccines is expected to increase the adoption over the forecast period. According to clinical trial results, Shingrix is highly efficient to prevent shingles and postherpetic neuralgia. Two doses of Shingrix are more than 90% effective to prevent the disease in adults aged 50 years and above. Protection stays above 85% for at least the first four years after getting vaccinated.

The availability of vaccines at lower prices, coupled with a high incidence of the disease and high vaccination rate in developed countries, is anticipated to fuel the market growth. The vaccination rate against shingles in the U.K., the U.S., France, Canada, Germany, and South Korea is higher compared to other countries owing to better reimbursement policies and high awareness levels regarding the disease and vaccines. For instance, the U.K. has the highest shingles vaccine uptake with more than 60% vaccination of eligible adults.

Shingles Vaccine Market Report Highlights

By product, Shingrix held the largest share in 2020 owing to the high efficacy of the vaccine as compared to others. Shingrix is also expected to grow at a significant CAGR over the forecast period owing to the increasing recommendations by regulatory bodies to prevent shingles

Based on vaccine type, the recombinant vaccine segment is anticipated to grow at a substantial rate over the forecast period due to the low risk associated with recombinant vaccines

Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and the rising adoption of vaccination programs in the region

North America dominated the market in 2020 due to favorable reimbursement policies and rising initiatives to raise awareness among healthcare professionals and patients

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market Segmentation and Scope
 - 1.1.1 segment scope
 - 1.1.2 regional scope
 - 1.1.3 Estimates and Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
 - 1.3.1 Purchased Database
 - 1.3.2 Secondary Sources
 - 1.3.3 Primary Research
 - 1.3.4 GVR's Internal Database
- 1.4 Information or Data Analysis
 - 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
 - 1.6.1 Commodity Flow Analysis
 - 1.6.1.1 Approach: Commodity Flow Approach
- 1.7 Global Market: CAGR Calculation
- 1.8 List of Secondary Sources
- 1.9 List of Abbreviations
- 1.10 Objectives
 - 1.10.1 Objective
 - 1.10.2 objective

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Market Outlook

CHAPTER 3 SHINGLES VACCINE MARKET VARIABLES, TRENDS & SCOPE

- 3.1 Shingles Vaccine Market Lineage Outlook
 - 3.1.1 Parent market outlook
 - 3.1.2 Ancillary market
- 3.2 Penetration & Growth Prospect Mapping
- 3.3 Market Dynamics
 - 3.3.1 Market driver analysis

- 3.3.1.1 Increasing risk of developing shingles
- 3.3.1.2 Increase in the recommendation of shingles vaccination
- 3.3.1.3 Cost-effectiveness of vaccination
- 3.3.2 Market restraint analysis
 - 3.3.2.1 Low awareness regarding shingles
 - 3.3.2.2 Weak product pipeline
- 3.4 Clinical Laboratory Services Market Analysis Tools
 - 3.4.1 Porter's Five Forces Analysis
 - 3.4.2 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
 - 3.4.2.1 Political And Legal
 - 3.4.2.2 Economic & Social
 - 3.4.2.3 Technological

CHAPTER 4 SHINGLES VACCINE MARKET: SEGMENT ANALYSIS, BY PRODUCT, 2017 - 2028 (USD MILLION)

- 4.1 Shingles Vaccine Market: Product Movement Analysis
 - 4.1.1 Shingrix
 - 4.1.1.1 Shingrix market estimates and forecast, 2017 - 2028
 - 4.1.2 Zostavax
 - 4.1.2.1 Zostavax market estimates and forecast, 2017 - 2028
 - 4.1.3 SKYZoster
 - 4.1.3.1 SKYZoster market estimates and forecast, 2017 - 2028

CHAPTER 5 SHINGLES VACCINE MARKET: SEGMENT ANALYSIS, BY VACCINE TYPE, 2017 - 2028 (USD MILLION)

- 5.1 Shingles Vaccine Market: Vaccine Type Movement Analysis
 - 5.1.1 Recombinant vaccine
 - 5.1.1.1 Recombinant vaccine market estimates and forecast, 2017 - 2028
 - 5.1.2 Live attenuated Vaccine
 - 5.1.2.1 Live attenuated vaccine market estimates and forecast, 2017 - 2028

CHAPTER 6 SHINGLES VACCINE MARKET: SEGMENT ANALYSIS, BY REGION, 2017 - 2028 (USD MILLION)

- 6.1 Shingles Vaccine Market: Regional Movement Analysis
 - 6.1.1 North America
 - 6.1.2 North America, SWOT Analysis

- 6.1.2.1 North America market estimates and forecast, 2017 - 2028
- 6.1.2.2 U.S.
 - 6.1.2.2.1 U.S. market estimates and forecast, 2017 - 2028
- 6.1.2.3 Canada
 - 6.1.2.3.1 Canada market estimates and forecast, 2017 - 2028
- 6.1.3 Europe
- 6.1.4 Europe, SWOT Analysis
 - 6.1.4.1 Europe market estimates and forecast, 2017 - 2028
 - 6.1.4.2 U.K.
 - 6.1.4.2.1 U.K. market estimates and forecast, 2017 - 2028
 - 6.1.4.3 Germany
 - 6.1.4.3.1 Germany market estimates and forecast, 2017 - 2028
 - 6.1.4.4 France
 - 6.1.4.4.1 France market estimates and forecast, 2017 - 2028
 - 6.1.4.5 Spain
 - 6.1.4.5.1 Spain market estimates and forecast, 2017 - 2028
 - 6.1.4.6 Italy
 - 6.1.4.6.1 Italy market estimates and forecast, 2017 - 2028
- 6.1.5 Asia Pacific
- 6.1.6 Asia Pacific, SWOT Analysis
 - 6.1.6.1 Asia Pacific market estimates and forecast, 2017 - 2028
 - 6.1.6.2 Japan
 - 6.1.6.2.1 Japan market estimates and forecast, 2017 - 2028
 - 6.1.6.3 China
 - 6.1.6.3.1 China market estimates and forecast, 2017 - 2028
 - 6.1.6.4 Australia
 - 6.1.6.4.1 Australia market estimates and forecast, 2017 - 2028
 - 6.1.6.5 South Korea
 - 6.1.6.5.1 South Korea market estimates and forecast, 2017 - 2028
- 6.1.7 Latin America
- 6.1.8 Latin America, SWOT Analysis
 - 6.1.8.1 Latin America market estimates and forecast, 2017 - 2028
 - 6.1.8.2 Brazil
 - 6.1.8.2.1 Brazil market estimates and forecast, 2017 - 2028
 - 6.1.8.3 Mexico
 - 6.1.8.3.1 Mexico market estimates and forecast, 2017 - 2028
- 6.1.9 Middle East and Africa
- 6.1.10 Middle East & Africa, SWOT Analysis
- 6.1.11 Middle East & Africa market estimates and forecast, 2017 - 2028

6.1.11.1 South Africa

6.1.11.1.1 South Africa market estimates and forecast, 2017 - 2028

CHAPTER 7 COMPETITIVE LANDSCAPE

7.1 Recent Developments & Impact Analysis, By Key Market Participants

7.1.1 Company/Competition Categorization (Key innovators, Market leaders, Emerging Players)

7.1.1.1 Vendor Landscape

7.1.1.1.1 Key company market share analysis, 2020

7.1.1.2 Public Companies

7.1.1.2.1 Company market position analysis, 2020

7.1.1.2.2 Competitive dashboard analysis

7.1.1.2.3 Synergy analysis: Major deals and strategic alliances

7.2 Company Profiles

7.2.1 GlaxoSmithKline plc.

7.2.1.1 Company overview

7.2.1.2 Financial performance

7.2.1.3 Product benchmarking

7.2.1.4 Strategic initiatives

7.2.2 Merck & Co., Inc.

7.2.2.1 Company overview

7.2.2.2 Financial performance

7.2.2.3 Product benchmarking

7.2.2.4 Strategic initiatives

7.2.3 SK chemicals

7.2.3.1 Company overview

7.2.3.2 Financial performance

7.2.3.3 Product benchmarking

7.2.3.4 Strategic initiatives

7.2.4 Green Cross Corp

7.2.4.1 Company overview

7.2.4.2 Curevo Vaccine

7.2.4.3 Financial performance

7.2.4.4 Product benchmarking

7.2.4.5 Strategic initiatives

7.2.5 CanSinoBIO

7.2.5.1 Company overview

7.2.5.2 Financial performance

- 7.2.5.3 Product benchmarking
- 7.2.5.4 Strategic initiatives
- 7.2.6 Geneone Life Science
 - 7.2.6.1 Company overview
 - 7.2.6.2 Product benchmarking
 - 7.2.6.3 Strategic initiatives
- 7.2.7 Vaccitech
 - 7.2.7.1 Company overview
 - 7.2.7.2 Product benchmarking
 - 7.2.7.3 Strategic initiatives

List Of Tables

LIST OF TABLES

Table 1 List of Secondary Sources

Table 2 List of Abbreviation

Table 3 North America Shingles Vaccine Market, By Country, 2017 - 2028 (USD Million)

Table 4 North America Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 5 North America Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 6 U.S. Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 7 U.S. Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 8 Canada Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 9 Canada Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 10 Europe Shingles Vaccine Market, By Country, 2017 - 2028 (USD Million)

Table 11 Europe Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 12 Europe Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 13 Germany Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 14 Germany Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 15 U.K. Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 16 U.K. Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 17 France Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 18 France Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 19 Italy Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 20 Italy Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 21 Spain Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 22 Spain Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 23 Asia Pacific Shingles Vaccine Market, By Country, 2017 - 2028 (USD Million)

Table 24 Asia Pacific Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 25 Asia Pacific Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 26 Japan Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 27 Japan Shingles Vaccine Market, By Vaccine Type 2017 - 2028 (USD Million)

Table 28 China Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 29 China Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 30 Australia Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 31 Australia Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 32 South Korea Shingles Vaccine Market, By Product 2017 - 2028 (USD Million)

Table 33 South Korea Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 34 Latin America Shingles Vaccine Market, By Country, 2017 - 2028 (USD Million)

Table 35 Latin America Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 36 Latin America Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 37 Brazil Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 38 Brazil Shingles Vaccine Market, By Vaccine Type 2017 - 2028 (USD Million)

Table 39 Mexico Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 40 Mexico Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 41 Middle East & Africa Shingles Vaccine Market, By Country, 2017 - 2028 (USD Million)

Table 42 Middle East & Africa Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 43 Middle East & Africa Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

Table 44 South Africa Shingles Vaccine Market, By Product, 2017 - 2028 (USD Million)

Table 45 South Africa Shingles Vaccine Market, By Vaccine Type, 2017 - 2028 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 Penetration & growth prospect mapping
- Fig. 2 Market driver relevance analysis (Current & future impact)
- Fig. 3 Market restrain relevance analysis (Current & future impact)
- Fig. 4 Porter's five forces analysis
- Fig. 5 Shingles vaccine market: Product outlook and key takeaways
- Fig. 6 Shingles vaccine market: Product movement analysis
- Fig. 7 Shingrix market estimates and forecast, 2017 - 2028
- Fig. 8 Zostavax market estimates and forecast, 2017 - 2028
- Fig. 9 SkyZoster market estimates and forecast, 2017 - 2028
- Fig. 10 Shingles vaccine market: Vaccine type outlook and key takeaways
- Fig. 11 Shingles vaccine market: Vaccine type movement analysis
- Fig. 12 Recombinant vaccine market estimates and forecast, 2017 - 2028
- Fig. 13 Live attenuated vaccine market estimates and forecast, 2017 - 2028
- Fig. 14 Shingles vaccine market: Regional outlook and key takeaways
- Fig. 15 Shingles vaccine market: Regional movement analysis
- Fig. 16 North America
- Fig. 17 North America, SWOT
- Fig. 18 North America. market estimates and forecast, 2017 - 2028
- Fig. 19 U.S.
- Fig. 20 U.S. market estimates and forecast, 2017 - 2028
- Fig. 21 Canada
- Fig. 22 Canada market estimates and forecast, 2017 - 2028
- Fig. 23 Europe
- Fig. 24 Europe, SWOT
- Fig. 25 Europe market estimates and forecast, 2017 - 2028
- Fig. 26 U.K.
- Fig. 27 U.K. market estimates and forecast, 2017 - 2028
- Fig. 28 Germany
- Fig. 29 Germany market estimates and forecast, 2017 - 2028
- Fig. 30 France
- Fig. 31 France market estimates and forecast, 2017 - 2028
- Fig. 32 Spain
- Fig. 33 Spain market estimates and forecast, 2017 - 2028
- Fig. 34 Italy
- Fig. 35 Italy market estimates and forecast, 2017 - 2028

Fig. 36 Asia Pacific

Fig. 37 Asia Pacific, SWOT

Fig. 38 Asia Pacific market estimates and forecast, 2017 - 2028

Fig. 39 Japan

Fig. 40 Japan market estimates and forecast, 2017 - 2028

Fig. 41 China

Fig. 42 China market estimates and forecast, 2017 - 2028

Fig. 43 Australia

Fig. 44 Australia market estimates and forecast, 2017 - 2028

Fig. 45 South Korea

Fig. 46 South Korea market estimates and forecast, 2017 - 2028

Fig. 47 Latin America

Fig. 48 Latin America, SWOT

Fig. 49 Latin America. market estimates and forecast, 2017 - 2028

Fig. 50 Brazil

Fig. 51 Brazil market estimates and forecast, 2017 - 2028

Fig. 52 Mexico

Fig. 53 Mexico market estimates and forecast, 2017 - 2028

Fig. 54 Middle East & Africa

Fig. 55 Middle East & Africa, SWOT

Fig. 56 MEA market estimates and forecast, 2017 - 2028

Fig. 57 South Africa

Fig. 58 South Africa market estimates and forecast, 2017 - 2028

I would like to order

Product name: Shingles Vaccine Market Size, Share & Trends Analysis Report By Product (Shingrix, Zostavax, SkyZoster), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine), By Region, And Segment Forecasts, 2021 - 2028

Product link: <https://marketpublishers.com/r/S29C80BA15CAEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S29C80BA15CAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970